Ken Griffin Better Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.14 - $0.39 $26,599 - $74,099
189,999 Added 726.13%
216,165 $43,000
Q3 2023

Nov 14, 2023
BUY
$0.34 - $1.23 $8,896 - $32,184
26,166 New
26,166 $9,000

Others Institutions Holding BTTX

# of Institutions
1
Shares Held
3K
Call Options Held
0
Put Options Held
0
View Full List

About Better Therapeutics, Inc.

BTTX Quotes by TradingView
  • Ticker BTTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,743,000
  • Description
  • Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional ...
More about BTTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email